Physician profile
Tod Northrup
NPI 1386622496
$126,845.68
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $16K · 2021: $18K · 2022: $12K · 2023: $27K · 2024: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Travel and Lodging: $2,561 · Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,400.00 |
| Travel and Lodging | $2,561.05 |
| Food and Beverage | $423.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omnilife Science, INC | $122,089.44 | 2019-2024 | Omnibotics 3.0, Omnibotics V 2.7, Various Products |
| Team 1, LLC | $3,523.83 | 2022-2023 | |
| Corin USA | $735.43 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $224.59 | 2020-2024 | Exparel, Zilretta, Iovera |
| Wright Medical Technology, INC. | $111.87 | 2020 | |
| Smith+Nephew, INC. | $39.19 | 2019 | |
| Zimmer Biomet Holdings, INC. | $31.55 | 2020 | |
| Heron Therapeutics, INC. | $25.25 | 2021-2022 | |
| Arthrex, INC. | $24.00 | 2023 | |
| Horizon Therapeutics Plc | $16.10 | 2023 | Krystexxa |
| Sonex Health, INC. | $12.33 | 2021 | |
| Theragen, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tod Northrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.